γ-Aminobutyric acid(A) agonists differentially augment gnawing induced by indirect-acting dopamine agonists in C57BL/6J mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 1, 1998, Pages 116-124

  Tirelli, Ezio ^a,b   Geter Douglass, Beth ^a   Witkin, Jeffrey M ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c NIDA Addiction Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMFONELIC ACID; AMPHETAMINE; APOMORPHINE; COCAINE; DICLOFENSINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABOXADOL; INDATRALINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MUSCIMOL; N (3 HYDROXYPHENETHYL) N (PHENETHYL)PROPYLAMINE; NOMIFENSINE; PERGOLIDE; VANOXERINE; (1R (EXO,EXO)) 3 (4 FLUOROPHENYL) 8 METHYL 8 AZABICYCLO(3.2.1)OCTANE 2 CARBOXYLIC ACID, METHYL ESTER; (1R-(EXO,EXO))-3-(4-FLUOROPHENYL)-8-METHYL-8- AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, METHYL ESTER; 4 AMINOBUTYRIC ACID A RECEPTOR; 4,5,6,7-TETRAHYDROISOXAZOLO(5,4-C)PYRIDIN-3-OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DRUG DERIVATIVE; ISOXAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GNAWING; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; BEHAVIOR, ANIMAL; COCAINE; DOPAMINE AGONISTS; ISOXAZOLES; MALE; MICE; MICE, INBRED C57BL; MUSCIMOL; PIPERAZINES; RECEPTORS, GABA-A;

EID: 0031594850     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Acri JB, Seidleck B and Witkin JM (1996) Effects of benztropine on behavioral and toxic effects of cocaine: Comparison with atropine and the selective dopamine uptake inhibitor l-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-propyl)-piperazine. J Pharmacol Exp Ther 277:198-206.
2. Akunne H, Dersch CM, Cadet JL, Char GU, Partilla JS, De Costa BR, Rice KC, Carroll FI and Rothman RB (1994) Studies of the biogenic amine transporters. III. Demonstration of two binding sites for [3H]GBR 12935 and [3H]BTCP in rat caudate membranes. J Pharmacol Exp Ther 268:1462-1475.
3. 3H]GBR 12935 binding in vivo in mouse brain: Labelling of a piperazine acceptor site. Eur J Pharmacol 144:1-6.
4. Arnt J (1987) Behavioral studies of dopamine receptors: evidence for regional selectivity and receptor multiplicity, in Dopamine Receptors (Creese I and Fraser CM eds) pp 199-231, Alan R. Liss Inc., New York.
5. Arnt J, Christensen AV and Scheel-Krüger J (1979) Benzodiazepines potentiate GABA-dopamine stereotyped dependent gnawing mice. J Pharm Pharmacol 31: 56-58.
6. Beauregard M and Ferron A (1991) Dopamine modulates the inhibition induced by GABA in rat cerebral cortex: an iontophoretic study. Eur J Pharmacol 205:225-231.
7. Benus RF, Bohus B, Koolhaas JM and Van Oortmerssen GA (1991) Behavioural differences between artificially selected aggressive and non-aggressive mice: Response to apomorphine. Behau Brain Res 43:203-208.
8. Berger P, Elsworth JD, Reith MEA, Tanen D and Roth RH (1990) Complex interaction of cocaine with dopamine uptake carrier. Eur J Pharmacol 176:251-252.
9. Bergman J, Madras BK, Johnson SE and Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251:150-155.
10. Broadbent J, Michael EK, Riddle EE and Appel JB (1991) Involvement of dopamine uptake in the discriminative stimulus effects of cocaine. Behav Pharmacol 2:187-197.
11. Casey DE (1995) Tardive dyskinesia: Pathophysiology, in Psyctiopharmacology: The Forth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1497-1502, Raven Press, New York.
12. Chiodo LA and Berger TW (1986) Interaction between dopamine and amino-acid induced excitation and inhibition in the striatum. Brain Res 375:198-203.
13. Cools AR (1977) Basic considerations on the role of concertedly working dopaminergic, GABA-ergic, cholinergic and serotoninergic mechanisms within the neostriatum and nucleus accumbens in locomotor activity, stereotyped gnawing, turning and dyskinetic activities. Adv Behav Biol 21:97-141.
14. Cooper SJ and Dourish CT (1990) An introduction to the concept of stereotypy and a historical perspective on the role of brain dopamine, in Neurobiology of Stereotyped Behaviour (Cooper SJ and Dourish CT eds) pp 1-24, Oxford University Press, Oxford.
15. Dersch CM, Akunne HC, Partilla JS, Char GU, De Costa BR, Rice KC, Carroll FI and Rothman RB (1994) Studies of the biogenic amine transporters I. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains. Neurochem Res 19:201-208.
16. Delini-Stula A (1979) Differential effects of baclofen and muscimol on behavioral responses implicating GABA-ergic transmission, in GABA-Neurotransmitters (Krogsgaard-Larsen P, Scheel-Krüger J and Kofod H eds) pp 482-498, Munskgaard, Copenhagen.
17. Ebert B, Wafford KA, Whiting PJ, Krogsgaard-Larsen P and Kemp JA (1994) Molecular pharmacology of gamma-aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different alpha, beta and gamma receptor subunit combinations. Mol Pharmacol 46:957-963.
18. Eilam D, Talanghayan H, Canaran G and Szechtman H (1992) Dopaminergic control of locomotion, mouthing, snout contact, and grooming: Opposing roles of D1 and D2 receptors. Psychopharmacology 106:447-454.
19. Elmer GI, Brockington A, Gorelick DA, Carrol FI, Rice KC, Matecka D, Goldberg SR and Rothman RB (1996) Cocaine cross-sensitization to dopamine uptake inhibitors: Unique effects of GBR 12909. Pharmacol Biochem Behav 53:911-918.
20. Elsworth JD, Taylor JR, Berger P and Roth RH (1993) Cocaine-sensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens and striatum. Neurochem Int 23:61-69.
21. Fonnum F (1987) Biochemistry, anatomy, and pharmacology of gaba, in Psychopharmacology: The Third Generation of Progress (Meltzer Hy ed) pp 173-182, Raven Press, New York.
22. Gerfen CR (1992) D1 and D2 dopamine receptor regulation of striatonigral and striatopallidal neurons. Semin Neurosci 4:109-118.
23. Giros B, Wang YM, Suter S, Mcleskeys SB, Pifl C and Caron M (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 269: 15985-15988.
24. Griffiths RR, Brady JV and Bradford LD (1979) Predicting the abuse liability of drugs with animal drug self-administration procedures: Psychomotor stimulants and hallucinogens, in Advances in Behavioral Pharmacology (Thompson T and Dews PB eds) vol 2, pp 163-208, Academic Press, New York.
25. Hadfield MG and Nugent EA (1983) Cocaine: Comparative effects on dopamine uptake in extrapyramidal and Iimbic systems. Biochem Pharmacol 32:744-746.
26. Hammerstad JP, Gronke L, Nutt J and Casey D (1980) The effects of gamma-vinyl GABA on amphetamine stereotypy in rats. Brain Res Bull 5:suppl 2, 609-612.
27. Izenwasser SI, Terry P, Heller B, Witkin JM and Katz JL (1994) Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors. Eur J Pharmacol 263:277-283.
28. Izenwasser S, Werling LL and Cox B (1990) Comparison of the effects of cocaine and other inhibitors of dopamine uptake in rat striatum, nucleus accumbens, olfactory tubercle and medial prefrontal cortex. Brain Res 520:303-309.
29. Johanson C-E and Fischman MM (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-52.
30. Johanson C-E and Schuster CR (1995) Cocaine, in Psychopharmacology: The Forth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1685-1688, Raven Press, New York.
31. 3H]mazindol binding sites from alkylation by N-ethylmaleimide. Eur J Pharmacol 227:411-415.
32. Kahn RS and Davis KL (1995) New developments in dopamine and schizophrenia, in Psychopharmacology: The Forth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1193-1204, Raven Press, New York.
33. Karoum F, Chrapusta SJ, Brinjak R, Hitri A and Wyatt RJ (1994) Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br J Pharmacol 113:1391-1399.
34. Kitayama S, Shimada S, Xu H., Markham L, Donovan DM and Uhl GR (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89:7782-7785.
35. A receptor agonists, partial agonists, and antagonists. Design and therapeutic prospects. J Med Chem 37:2489-2505.
36. Lew R, Grigoriadis D, Wilson A, Boja JW, Simantov R and Kuhar M (1991) Dopamine transporters: Deglycosylation with exo-and endoglycosidases. Brain Res 539: 239-246.
37. Ljundberg T and Ungerstedt U (1977) Apomorphine-induced locomotion and gnawing: evidence the experimental design greatly influences gnawing while locomotion remains unchanged. Eur J Pharmacol 46:147-151.
38. Lloyd KG and Morselli PL (1987) Psychopharmacology of GABAergic drugs, in Psychopharmacology: The Third Generation of Progress (Meltzer HY ed) pp. 183-194, Raven Press, New York.
39. A/benzodiazepine receptor heterogeneity: Neurophysiological implications. Neuropharmacology 34:245-254.
40. Madras BK, Fahey MA, Bergman J, Canfield DR and Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. I. [3H]Cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251:131-141.
41. Marascuilo LA and Serlin RC (1988) Statistical Methods for the Social and Behavioral Sciences part IV, pp 407-440, Freeman and Company, New York.
42. Meiergerd SM and Schenk JO (1994) Kinetic evaluation of the commonality between the site(s) of action of cocaine and some other structurally similar and dissimilar inhibitors of the striatal transporter for dopamine. J Neurochem 63:1683-1692.
43. Melia KF and Spealman RD (1991) Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J Pharmacol Exp Ther 258:626-632.
44. Meltzer PC, Liang AY and Madras BK (1994) The discovery of an unusually selective and novel cocaine analog: Difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J Med Chem 37:2001-2010.
45. - currents in nigral neurons in slices, in GABAergic Synoptic Transmission, Advances in Biochemical Psychopharmacology (Biggio G, Concas A and Costa E eds) vol 47, pp 179-201, Raven Press, New York.
46. Mogenson GJ ( 1987) Limbic-motor integration. Prog Psychobiol Physiol Psychol 12: 117-170.
47. Newman AH, Allen AC, Izenwasser S and Katz JL (1994) Novel 3α-(diphenylmethoxy)tropane analogs: Potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J Med Chem 37: 2258-2261.
48. 3H]GBR 12,935 binding. Mol Pharmacol 45:125-135.
49. Randrup A, Sorensen G and Kobayashi M (1988) Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: Relation to disintegrated behaviour, brain dopamine and psychiatric disease. Jpn J Psychopharmacol 8:313-327.
50. Reith MEA and Selmeci G (1992) Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol, and GBR 12935. Naunyn-Schmiedeberg's Arch Pharmacol 345:309-318.
51. Risch C, Kripke D and Janowsky D (1980) Flurazepam effects on methylphenidate-induced stereotyped behavior. Psychopharmacology 70:79-82.
52. Robbins TW and Sahakian BJ (1981) Behavioural and neurochemical determinants of stereotypy induced by drugs, in Metabolic Disorders of the Nervous System (Rose FC ed) pp 244-291, Pitman Press, London.
53. Rothman RB (1990) High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sci Pharmacol Lett 46:PL-17-PL-21.
54. Rothman RB and Glowa JR (1995) A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Mol Neurobiol 11:1-19.
55. Rothman RB, Mele A, Reid AA, Akunne H, Greig N, Thurkauf A, Rice KC and Pert A (1989) Tight binding dopamine reuptake inhibitors as cocaine antagonists FEBS Lett 257: 341-344.
56. Rothman RB, Mele A, Reid AA, Akunne HC, Greig N, Thurkauf A, Decosta BR, Rice KC and Pert A (1991) GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behau 40:387-397.
57. Scheel-Krüger J (1986) Dopamine-Gaba interactions: Evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neural Scand 73:suppl 107, 9-54.
58. Scheel-Krüger J, Arnt J, Braestrup C, Christensen AV and Magelund G (1979) Development of new animal models of GABA-ergic actions using muscimol as a tool, in GABA-Neurotransmitters (Krogsgaard-Larsen P, Scheel-Krüger J, Kofod H eds) pp 447-464, Munksgaard, Copenhagen.
59. Scheel-Krüger J, Christensen AV and Arnt J (1978) Muscimol differentially facilitates stereotypy but antagonizes motility induced by dopaminergic drugs: A complex GABA-dopamine interaction. Life Sci 22:75-84.
60. Schuster CR and Johanson CE (1988) Relationship between the discriminative stimulus properties and subjective effects of drugs, in Psychopharmacology, Series 4: Transduction Mechanisms of Drug Stimuli (Colpaert FC and Balster RL eds) pp 161-175, Springer, Berlin.
61. Tirelli E (1987) Ontogeny of GABAergic and dopaminergic mediation of gnawing behaviour in the mouse. Psychopharmacology 92:89-95.
62. Tirelli E and Witkin JM (1995) Differential effects of direct and indirect agonists on the induction of gnawing in C57BL/6J mice. J Pharmacol Exp Ther 273:7-15.
63. Van Der Zee P, Koger HS, Gootjes J and Hespe W (1980) Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur J Med Chem 15:363-370.
64. Vaugeois J-M, Bonnet J-J, Duterte-Boucher D and Costentin J (1993) In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230:195-201.
65. Vaughan RA (1995) Photoaffinity-labeled ligand binding domains on dopamine transportors identified by peptide mapping. Mol Pharmacol 47:956-964.
66. Vaughan RA and Kuhar MJ (1996) Dopamine transporter ligand binding domains: Structural and functional properties revealed by limited proteolysis. J Biol Chem 271:21672-21680.
67. Walters JR and Pucak ML (1996) The modulation of dopaminergic systems by gaba, in The Modulation of Dopaminergic Neurotransmission by Other Neurotransmitters (Ashby Jr CR ed) CRC Press, Boca Raton.
68. Waszcak BL and Walters JR (1983) Dopamine modulation of the effects of gammaaminobutyric acid on substantia nigra pars reticulata neurons. Science 220:218-221.
69. Witkin JM (1994) Pharmacotherapy of cocaine abuse: Preclinical development. Neurosci Biobehav Rev 18:121-142.
70. Witkin JM and Acri JB (1995) Effects of ifenprodil on stimulatory, discriminative stimulus, and convulsant effects of cocaine. Behau Pharmacol 6:245-253.
71. Witkin JM, Nichols DE, Terry P and Katz JL (1991) Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J Pharmacol Exp Ther 257:706-713.
72. Witkin JM, Tirelli E and Geter-Douglass B (1995) Behavioral and pharmacological differentiation of direct and indirect dopamine agonists and among dopamine uptake inhibitors. Natl Inst Drug Abuse Res Monogr Prob Drug Depend 153:512.
73. Worms P and Lloyd KG (1982) Biphasic effects of direct, but not indirect, GABA mimetics and antagonists on haloperidol-induced catalepsy. Naunyn-Schmiedeberg's Arch Pharmacol 311:179-184.